• Clinical and Experimental Pediatrics
• /
• 제64권7호
• /
• pp.370-372
• /
• 2021

• Archives of Plastic Surgery
• /
• 제49권1호
• /
• pp.132-136
• /
• 2022

• Clinical and Experimental Pediatrics
• /
• 제65권5호
• /
• pp.269-271
• /
• 2022

• 생명과학회지
• /
• 제33권9호
• /
• pp.746-753
• /
• 2023

바이러스성 전염병은 전 세계 공중 보건에 가장 큰 위협 중 하나로 간주된다. 최근 중증급성호흡기증후군 코로나바이러스-2(SARS-CoV-2)로 인한 COVID-19 대유행은 신종 바이러스 감염의 위협을 극명하게 상기시켜 주었다. 효율적인 백신과 치료제 개발 및 생산은 팬데믹을 퇴치할 수 있는 유일한 대안일 것이며 COVID-19 대유행은 새로운 바이러스성 질병을 통제하고 예방하기 위한 새로운 백신 플랫폼의 필요성을 보여주었다. 기존의 백신 플랫폼인 약독화 생백신, 불활성화 백신은 백신 개발 속도, 제조 등이 광범위한 백신 적용을 위한 긴급 사용에 한계가 있다. 흥미롭게도, COVID-19 예방을 위한 SARS-CoV-2 mRNA-지질나노입자(LNP) 플랫폼은 기존 백신 플랫폼 한계에 대한 효과적인 대안임이 확인되었다. 또한 COVID-19 mRNA 핵산 백신과 나노입자 기반 플랫폼은 SARS-CoV-2 및 변종 SARS-CoV-2 모두에 효과적인 백신임이 확인되었다. 이 논문에서는 mRNA 백신, 디지털 백신 및 나노입자백신 등의 차세대 백신 플랫폼을 중점으로 백신 기술 및 플랫폼의 장단점에 대해 기술하였다.

• Journal of Trauma and Injury
• /
• 제36권4호
• /
• pp.343-353
• /
• 2023

Purpose: The COVID-19 pandemic led to significant changes in the lifestyle patterns of children and affected the patterns of pediatric injuries. This study analyzed the changing patterns of pediatric injury overall and by age groups, based on the datasets before and during the COVID-19 pandemic. Methods: This study is based on the data of patients who presented with injuries at 23 hospital emergency departments participating in the Emergency Department-based Injury In-depth Surveillance (EDIIS) conducted by the Korea Disease Control and Prevention Agency. The surveillance data was categorized by injury mechanism, location, activity, and severity. We analyzed the injury patterns of pediatric patients aged 0 to 15 years. Subgroup analysis was conducted by age group in children aged 7 to 15 years, 1 to 6 years, and <1 year. Results: When comparing the COVID-19 pandemic period to the pre-COVID-19 period, the total number of pediatric patients with injuries decreased by 38.7%, while the proportions of in-home injuries (57.9% vs. 67.9%), and minor injuries (38.9% vs. 39.7%) increased. In the 7 to 15 years group, bicycle riding injuries (50.9% vs. 65.6%) and personal mobility device injuries (2.4% vs. 4.6%) increased. The 1 to 6 years group also showed an increase in bicycle accident injuries (15.8% vs. 22.4%). In the <1 year group, injuries from falls increased (44.5% vs. 49.9%). Self-harm injuries in the 7 to 15 years group also increased (1.6% vs. 2.8%). Conclusions: During the COVID-19 pandemic period, the overall number of pediatric injuries decreased, while injuries occurring at home and during indoor activities increased. Traffic accidents involving bicycles and personal mobility devices and self-harm injuries increased in the 7 to 15 years group. In the <1 year group, the incidence of falls increased. Medical and societal preparedness is needed so that we might anticipate these changes in the patterns of pediatric injuries during future infectious disease pandemics.

• Clinical and Experimental Pediatrics
• /
• 제63권4호
• /
• pp.125-132
• /
• 2020

Coronavirus disease-2019 (COVID-19), which started in Wuhan, China, in December 2019 and declared a worldwide pandemic on March 11, 2020, is a novel infectious disease that causes respiratory illness and death. Pediatric COVID-19 accounts for a small percentage of patients and is often milder than that in adults; however, it can progress to severe disease in some cases. Even neonates can suffer from COVID-19, and children may spread the disease in the community. This review summarizes what is currently known about COVID-19 in children and adolescents.

• Journal of Yeungnam Medical Science
• /
• 제41권3호
• /
• pp.150-157
• /
• 2024

The prevalence of childhood and adolescent obesity has increased and exacerbated during the coronavirus disease 2019 pandemic, both in Korea and globally. Childhood and adolescent obesity poses significant risks for premature morbidity and mortality. The development of serious comorbidities depends not only on the duration of obesity but also on the age of onset. Obesity in children and adolescents affects almost all organ systems, including the endocrine, cardiovascular, gastrointestinal, reproductive, nervous, and immune systems. Obesity in children and adolescents affects growth, cognitive function, and psychosocial interactions during development, in addition to aggravating known adult comorbidities such as type 2 diabetes mellitus, hypertension, dyslipidemia, nonalcoholic fatty liver disease, obstructive sleep apnea, and cancer. Childhood and adolescent obesity are highly associated with increased cardiometabolic risk factors and prevalence of metabolic syndrome. The risk of cardiovascular and metabolic diseases in later life can be considerably decreased by even a small weight loss before the onset of puberty. Childhood and adolescent obesity is a disease that requires treatment and is associated with many comorbidities and disease burdens. Therefore, early detection and therapeutic intervention are crucial.

• BMB Reports
• /
• 제55권9호
• /
• pp.465-471
• /
• 2022

Understanding and monitoring virus-mediated infections has gained importance since the global outbreak of the coronavirus disease 2019 (COVID-19) pandemic. Studies of high-throughput omics-based immune profiling of COVID-19 patients can help manage the current pandemic and future virus-mediated pandemics. Although COVID-19 is being studied since past 2 years, detailed mechanisms of the initial induction of dynamic immune responses or the molecular mechanisms that characterize disease progression remains unclear. This study involved comprehensively collected biospecimens and longitudinal multi-omics data of 300 COVID-19 patients and 120 healthy controls, including whole genome sequencing (WGS), single-cell RNA sequencing combined with T cell receptor (TCR) and B cell receptor (BCR) sequencing (scRNA(+scTCR/BCR)-seq), bulk BCR and TCR sequencing (bulk TCR/BCR-seq), and cytokine profiling. Clinical data were also collected from hospitalized COVID-19 patients, and HLA typing, laboratory characteristics, and COVID-19 viral genome sequencing were performed during the initial diagnosis. The entire set of biospecimens and multi-omics data generated in this project can be accessed by researchers from the National Biobank of Korea with prior approval. This distribution of large-scale multi-omics data of COVID-19 patients can facilitate the understanding of biological crosstalk involved in COVID-19 infection and contribute to the development of potential methodologies for its diagnosis and treatment.

• 의료법학
• /
• 제21권2호
• /
• pp.105-162
• /
• 2020

감염병의 팬데믹 상황 속에서, 국가의 방역 대책은 안보로서의 속성을 지니며, 공중보건과 공공의 이익의 이름으로 개인의 자유에 대한 일정한 제한이 정당화되어왔다. 2020년 3월, 대한민국 국회는 「감염병의 예방 및 관리에 관한 법률」 개정안을 통과시켰으며, 이를 통해 '감염의심자'의 검사 및 격리거부에 대한 처벌의 법적 근거를 신설하고 격리위반과 치료거부의 벌칙을 상향하였다. 본 논문에서는 국가가 개인의 자유를 제한하는 행위의 정당성 판별기준에 대한 자유주의 법철학의 논변과 원리들을 검토하고, 피해자임과 동시에 매개체로서의 속성을 지니는 감염병 환자(patient as victim and vector)에 대한 자유제한원리의 적용은 파인버그(Joel Feinberg)가 제시한 '스스로에 대한 해악(harm to self)'과 '타인에 대한 해악(harm to others)'이 중첩되는 지점에 있음을 개념화하였다. 파인버그가 제기한 자유제한원리(liberty-limiting principle)를 불확실성(uncertainty)을 지니는 팬데믹 상황에 적용하기 위해서는, 해악에서 리스크(risk)로 해악의 원리를 확장시킬 것이 요구된다. 이러한 해악에서 리스크로의 전환은, 불확실한 위기상황 하에서 국가가 사전주의 원칙(precautionary principle)을 통해 개인의 자유를 사전적으로 제한하는 것을 정당화함과 동시에, 충분한 근거 없이 개인의 행위를 처벌의 대상으로 삼는 과잉범죄화(overcriminalization)의 우려를 낳는다. 본 글에서는 리스크를 지닌 개인에 대한 사전적 자유제한을 둘러싼 사전주의의 원칙과 과잉범죄화의 우려 사이에서 균형을 이룰 수 있는 원칙들을 검토한다. 이어서 '타인에 대한 해악' 원칙이 공익과 공중보건 상황에 적용되기 위한 두 번째 확장으로, 인구집단 개념으로의 전환을 다룬다. 팬데믹과 같은 공중보건 위기 상황에서는 '개인'이 아닌 '인구집단'을 하나의 단위로 고려하는 인구집단 접근법(population approach)이 필요하며, 나아가 앞선 두 논의를 결합한 '인구집단에 대한 리스크(risk to population)'가 팬데믹 상황에서 해악의 원리의 중요한 구성요소로 고려되어야 함을 제안한다. 논문의 마지막에서는, 앞서 개념화한 '확장된 해악의 원리' 하에서 개정 「감염병의 예방 및 관리에 관한 법률」의 자유제한이 정당화될 수 있는지 검토한다. 격리위반 처벌조항은 '인구집단에 대한 리스크'에 대한 자유제한에 해당하여, 강제검사 또한 무증상 감염자라는 감염병의 특성에 의거하여 '확장된 해악의 원리'의 차원에서는 정당성이 부정되지 않음을 보일 수 있었다. 그러나 치료거부 처벌조항은 전통적 해악의 원리뿐만 아니라 '인구집단에 대한 리스크'라는 팬데믹의 특성을 고려한 '확장된 해악의 원리' 하에서도 정당화되기 어려우며, 추가적 단서조항을 포함하여야만 정당화 근거를 획득할 수 있을 것임을 논증하였다.

• BMB Reports
• /
• 제53권4호
• /
• pp.191-205
• /
• 2020

The unexpected pandemic set off by the novel coronavirus 2019 (COVID-19) has caused severe panic among people worldwide. COVID-19 has created havoc, and scientists and physicians are urged to test the efficiency and safety of drugs used to treat this disease. In such a pandemic situation, various steps have been taken by the government to control and prevent the Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2). This pandemic situation has forced scientists to rework strategies to combat infectious diseases through drugs, treatment, and control measures. COVID-19 treatment requires both limiting viral multiplication and neutralizing tissue damage induced by an inappropriate immune reaction. Currently, various diagnostic kits to test for COVID-19 are available, and repurposing therapeutics for COVID-19 has shown to be clinically effective. As the global demand for diagnostics and therapeutics continues to rise, it is essential to rapidly develop various algorithms to successfully identify and contain the virus. This review discusses the updates on specimens/samples, recent efficient diagnostics, and therapeutic approaches to control the disease and repurposed drugs mainly focusing on chloroquine/hydroxychloroquine and convalescent plasma (CP). More research is required for further understanding of the influence of diagnostics and therapeutic approaches to develop vaccines and drugs for COVID-19.